The high efficacy of new drugs for systemic mastocytosis is prompting consideration of "drug holidays." This would allow patients, who have a near-normal life expectancy, to temporarily stop treatment for major life events like planning a family. This signals a paradigm shift from continuous therapy to intermittent disease management for chronic conditions.

For non-advanced systemic mastocytosis, new drugs are differentiated by their side effect profiles, not just efficacy. Avapritinib can cause cognitive effects as it crosses the blood-brain barrier, while bezuclastinib may cause transient liver enzyme elevation. This allows for personalized treatment choices based on patient tolerability and lifestyle.

While regulators are open to using Patient-Reported Outcomes (PROs) for drug approval, the oncology community reflexively prioritizes survival data. This cultural bias sees PROs as "softer" endpoints, hindering the approval of drugs based on how patients feel and function.

Recent Phase 3 trials for novel myelofibrosis combinations (e.g., pelabrasib or selinexor with ruxolitinib) show a consistent pattern. They successfully reduce spleen volume but fail to demonstrate a statistically significant improvement in patient-reported symptom scores compared to ruxolitinib alone, questioning the link between these two endpoints.

AAVantgarde learned from its Usher syndrome trial that capturing patient-reported outcomes is essential, especially when traditional functional endpoints like eye charts are slow to change. This strategy ensures they capture meaningful data on patient quality of life, which can be crucial for demonstrating therapeutic benefit in slowly progressing diseases.

Pathologists are integral to ongoing patient management by monitoring treatment response. They track the variant allele frequency of KIT D816V in blood and assess mast cell reduction in follow-up biopsies to determine if therapies like TKIs are effective or if the disease is worsening, extending their role far beyond initial diagnosis.

Avapritinib is dosed at 200mg for advanced systemic mastocytosis (SM) but only 25mg for indolent SM. This tenfold difference is not based on tolerance but on the goal of therapy: extending survival in advanced SM versus improving quality of life without significant toxicity in indolent SM, where survival is near-normal.

In desmoid tumors, traditional RECIST criteria for tumor response are inadequate. Patients report significant improvements in pain and functional status even with minor tumor shrinkage that doesn't qualify as a partial response, making patient-reported outcomes a more meaningful endpoint.

While the FDA's primary endpoint for gout drugs is a simple biomarker (uric acid levels), Crystallis designed its Phase 3 trials around harder clinical endpoints like flare reduction. This forward-thinking strategy aims to generate data needed to convince payers of the drug's value, ensuring market access post-approval.